Abstract 865P
Background
The prognosis of early OSCC is strongly correlated with local disease control. However, patients with T1-T2 OSCC and clear margins have a 5-year local relapse rate of around 15%. The evaluation of the quality of surgical resection is therefore essential.
Methods
A prospective multicenter trial based on patients with T1-T2 OSCC treated surgically with clear margins, showed the interest of a molecular analysis (microsatellite instability (MSI)) of surgical margins to evaluate the minimal residual disease (MRD) while adapting the postoperative strategy (NCT00232960). Recently, innovative techniques for detecting circulating tumor DNA have been developed. Our main objective was, then, to evaluate the feasibility of detecting MRD by identifying specific molecular abnormalities with Whole Exom Sequencing (WES) and Shallow Whole Genome Sequencing (ShWGS) in the primary tumor and looking for it on the margins.
Results
310 patients were included initially with 216 tumor/margins samples available for molecular analysis. Tumor was informative for MSI analysis in 63% of cases (n=133). Positive molecular margins were observed in 23 cases, leading to a postoperative treatment. Median follow-up was 58 months [30;83]. In informative tumor, molecularly driven treatment seemed to lower the 5-year local recurrence rate from 14.1% to 6.4% (p=0.15). Among the initial cohort, 108 primary tumors were secondary screened by WES with an informative rate of 78.6%. With a 10X depth for molecular analysis, we observed 13 patients with at least one positive margin. Then, analyzing retrospectively the oncologic outcomes, we observed a significant benefit for local control at 5 years for patients with WES negative margins (91.7% versus 64.1%, p=0.02). We, then, performed a ShWGS analysis on a sub-group of 39 patients. Patients with positive margins both in WES and ShWGS had a higher risk of local relapse at 5 years (p<10-3).
Conclusions
Molecular analysis of surgical margins for early OSCC lead to a better assessment of microscopic residual disease while postoperative decision making according to WES and ShWGS could improve local control.
Clinical trial identification
NCT00232960.
Editorial acknowledgement
Legal entity responsible for the study
GETTEC group (French Group for Study of Head and Neck Tumors).
Funding
PHRC program from INCA (French National Cancer Institute) PRISM program from Gustave Roussy Cancer Campus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
942P - Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1092P - Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Presenter: Manja Bloem
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12